Cancer Research Institute: Combination Drug Strategies Gain Ground in PD-1/PD-L1 Pipeline
November 12, 2020
November 12, 2020
NEW YORK, Nov. 12 (TNSJou) -- Cancer Research Institute issued the following news:
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment. The report, titled "Combinations take centre stage in PD1/PDL1 inhibitor c . . .
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment. The report, titled "Combinations take centre stage in PD1/PDL1 inhibitor c . . .